Expert Interview
Discussing the data from the registrational Phase 2 FIREFLY-1 trial evaluating the investigational agent tovorafenib from Day One Bio in Low-Grade Glioma and Advance Solid Tumors
Ticker(s): DAWNInstitution: UCSF
- Full Professor and Neuro-oncologist in the UCSF Department of Neurological Surgery who specializes in the management of brain/spine tumors, neuro-imaging, cognitive and rehabilitative neurology and complementary therapy.
- Director of Translational Research in Neuro-Oncology, the Neuro-Oncology Fellowship Director, and Chair of the UCSF Cancer Center CNS Tumors Site Committee.
- PI on a wide range of clinical trials, including those with convection enhanced delivery (CED), surgical interventions, targeted agents, and immunotherapy with a particular interest and expertise in enriched patient clinical trials, phase 0/I/II trials which administer agents to patients prior to and following surgery, and precision medicine clinical trials.
What are your impressions of the data from the FIREFLY-1 trial.
Added By: wilson_adminHow will you use tovarafenib in LGG patients
Added By: wilson_adminHow does tovafenib compare against Tafinlar and Mekinist?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
